Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Placebos: Their Underappreciated Impact in Pharmaceutical Trials

Terence W. Starz, MD, Theodore Pincus, MD, On Behalf Of The ARHP Practice Committee  |  Issue: September 2018  |  September 20, 2018

Sir William Osler, the father of modern medicine, said “the desire to take medicine is perhaps the greatest feature that separates man from animal.” Determination of the benefit of a medication can be challenging and includes a number of factors, such as pharmacologic activities on the disease pathophysiology, pharmacokinetic properties and patient characteristics.1,2 An additional, often unrecognized or unappreciated, contributor, the placebo effect, also may be extraordinarily important in determining the response to a medication.3

At funerals in the Middle Ages, a common part of the funeral chant used by hired mourners (inauthentic behavior) began with the ninth verse of Psalm 116, Placebo Domino in regione vivorum, which in the Latin Vulgate translation means “I shall please the Lord in the land of the living.” This inauspicious connotation of placebo, representing falsehood, persisted, and the term was subsequently employed medically starting in the late 1700s to describe fake treatments given for a variety of diseases.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In that era of therapeutic adventure and misadventure, the cure—in widespread and unregulated use—was frequently worse than the illness (e.g., major surgery without anesthesia; use of powerful electrical devices). As a result, kinder and gentler interventions were often tried. It was recognized that treatments with inert substances, such as sugar or bread pills, and highly diluted preparations, such as used in homeopathy, could be associated with clinical benefit. Was this effect just the body’s natural healing processes, or was something else involved? Since that time, placebos have been used both therapeutically and as important methodologic tools in research.

Placebo is defined as an inert substance with no measurable biological effect that is used to please an individual rather than to provide a pharmacological effect on a disorder. A placebo group is included in clinical trials to help differentiate pharma­ceutical effects of an active intervention from nonpharmaceutical effects resulting from the natural course of disease, inherent healing processes, patient expectations of the treatment, messages conveyed by the doctor and others.3,4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When patients in routine clinical care report that a certain medication is of no value and/or even makes them feel worse, they should not be told the treatment should be efficacious on the basis of reported evidence. The evidence is reported for patient groups, while individual patients often differ widely in responses to treatments or placebos.

Research Says …

Considerable debate and research exists concerning placebo and nocebo (negative placebo) effects in clinical trials involving rheumatic diseases, particularly osteoarthritis (OA), low back pain, depression and fibromyalgia, in which symptoms are affected by neural processing in specific areas of the brain.5-8

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Drug Updates Tagged with:clinical trialsplacebo

Related Articles

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    Is Acupuncture for Pain a Placebo Treatment?

    November 1, 2010

    An examination of the evidence

    The Science of MDHAQ/RAPID3 Scores

    December 12, 2011

    Do patient self-reports provide valid data for evidence-based care in rheumatology practice?

    Mitigate Risk and Increase Success of Lupus Clinical Trials

    August 1, 2010

    Design strategies from a Lupus Research Institute conference

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences